Why Most Wellness Trends and Supplements Are Ineffective: A Medical Perspective

Hepatitis B surface antigen, commonly known as HBsAg, is a protein found on the surface of the hepatitis B virus. This antigen is the first marker to appear in the blood when someone becomes infected with hepatitis B. The presence of HBsAg in a blood sample indicates that the person is currently infected with the virus and can potentially transmit it to others. Testing for HBsAg is one of the most important laboratory tests for diagnosing acute and chronic hepatitis B infection.

The HBsAg test is typically performed using a blood sample drawn from a vein. Healthcare providers order this test when screening for hepatitis B infection, evaluating liver disease, checking pregnant women during prenatal care, or monitoring people at high risk for hepatitis B exposure. High-risk groups include healthcare workers, people who inject drugs, individuals with multiple sexual partners, those receiving dialysis, and people born in regions where hepatitis B is common. The test can detect the antigen as early as one to two weeks after infection, often before symptoms appear.

A positive HBsAg result means that hepatitis B virus is present in the blood. If the antigen remains detectable for more than six months, the infection is considered chronic. A negative result generally means the person is not currently infected, although very early infection or past resolved infection may also show negative results. For this reason, healthcare providers often order additional tests such as hepatitis B surface antibody and hepatitis B core antibody to get a complete picture of a person's hepatitis B status.

People with a positive HBsAg test should avoid donating blood, organs, or tissue. They should also take precautions to prevent spreading the virus to others through blood or body fluids. Additional testing is usually recommended to assess liver function and determine whether treatment is needed. Regular monitoring of HBsAg levels, along with other liver tests, helps healthcare providers track the progression of the disease and evaluate the effectiveness of antiviral treatments. Vaccination is available for people who test negative and are at risk of exposure to hepatitis B.